Inhibikase Therapeutics (IKT) Cash from Operations (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Cash from Operations of 12059722.0 for Q1 2026, down 193.89% year-over-year from 12844996.79 in Q1 2025, and down 60.45% quarter-over-quarter from 7515973.0 in Q4 2025.
Inhibikase Therapeutics (IKT) Cash from Operations (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Cash from Operations for 7 consecutive years, with 12059722.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 193.89% year-over-year to 12059722.0; the TTM figure through Mar 2026 stood at 35742656.0 (down 84.39% YoY), while the FY2025 annual figure was 27786464.0, down 45.11% from the prior year.
- Cash from Operations retreated to 12059722.0 in Q1 2026 per IKT's latest filing, from 7515973.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 3442431.0 in Q4 2023 and bottomed at 12059722.0 in Q1 2026.
- Historically, Cash from Operations has averaged 5554729.35 across 5 years, with a median of 4881100.0 in 2024.
- Annual changes were most pronounced in 2024 — Cash from Operations jumped 35.25% — and 2026, when it plunged 193.89%.
- Inhibikase Therapeutics' Cash from Operations stood at 3556374.0 in 2022, then grew by 3.2% to 3442431.0 in 2023, then plunged by 55.28% to 5345575.0 in 2024, then slumped by 40.6% to 7515973.0 in 2025, then tumbled by 60.45% to 12059722.0 in 2026.
- Business Quant data shows IKT's Cash from Operations at 12059722.0 in Q1 2026, 7515973.0 in Q4 2025, and 10592730.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | -12.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.44 Mn |
| Jun 30, 2026 | -12.44 Mn |
| Mar 31, 2026 | -12.06 Mn |
| Mar 31, 2026 | -12.06 Mn |
| Dec 31, 2025 | -7.52 Mn |
| Dec 31, 2025 | -7.52 Mn |
| Sep 30, 2025 | -10.59 Mn |
| Sep 30, 2025 | -10.59 Mn |
| Jun 30, 2025 | -5.57 Mn |
| Jun 30, 2025 | -5.57 Mn |
| Mar 31, 2025 | -4.10 Mn |
| Mar 31, 2025 | -4.10 Mn |
| Dec 31, 2024 | -5.35 Mn |
| Dec 31, 2024 | -5.35 Mn |
| Sep 30, 2024 | -4.88 Mn |
| Sep 30, 2024 | -4.88 Mn |
| Jun 30, 2024 | -5.05 Mn |
| Jun 30, 2024 | -5.05 Mn |
| Mar 31, 2024 | -3.87 Mn |
| Mar 31, 2024 | -3.87 Mn |